Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Angiolink Corporation was a medical device company that specialized in the development of vascular closure systems. The company's primary product, the E-Seal Vascular Closure Device, was designed to seal femoral artery punctures after catheterization procedures. This technology utilized a mechanical staple to achieve hemostasis, offering an alternative to manual compression or collagen-based plugs. In October 2004, Angiolink was acquired by Medtronic for approximately $45 million to expand its portfolio of interventional vascular products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Angiolink.